Patents by Inventor Martin John Calverley

Martin John Calverley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8759555
    Abstract: The present invention relates to intermediates useful for the synthesis of calcipotriol or calcipotriol monohydrate, to methods of producing said intermediates, and to methods of stereoselectively reducing said intermediates.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: June 24, 2014
    Assignee: Leo Pharma A/S
    Inventors: Thomas Peter Sabroe, Martin John Calverley
  • Patent number: 8455466
    Abstract: Compounds according to formula I in which formula R1 and R2, which may be the same or different, represent halogen, (C1-C6)hydrocarbyl, optionally substituted with one or two hydroxyl group or one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C3-C6)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C1-C3)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: June 4, 2013
    Assignee: Leo Pharma A/S
    Inventors: Ernst Torndal Binderup, Kai Holst Hansen, Claus Aage Svensgaard Bretting, Martin John Calverley
  • Patent number: 8362287
    Abstract: The present invention relates to intermediates useful for the synthesis of calcipotriol or calcipotriol monohydrate, to methods of producing said intermediates, and to methods of stereoselectively reducing said intermediates.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: January 29, 2013
    Assignee: Leo Pharma A/S
    Inventors: Thomas Peter Sabroe, Martin John Calverley
  • Publication number: 20120271058
    Abstract: The present invention relates to intermediates useful for the synthesis of calcipotriol or calcipotriol monohydrate, to methods of producing said intermediates, and to methods of stereoselectively reducing said intermediates.
    Type: Application
    Filed: June 26, 2012
    Publication date: October 25, 2012
    Inventors: Thomas Peter SABROE, Martin John Calverley
  • Patent number: 6399797
    Abstract: The present invention relates to compounds of formula (I), in which formula X is hydrogen or hydroxy or protected hydroxy; R1 an R2 stand for hydrogen, methyl or ethyl, or, when taken together with the carbon atom bearing the group X, R1 and R2 can form a C3-C5 carbocyclic ring; Q is a C3-C6 hydrocarbylene, hydrocarbylene indicating the diradical obtained after removal of 2 hydrogen atoms for a straight or banched, saturated or unsaturated hydrocarbon, in which one of any CH2 groups may optionally be replaced by an oxygen atom or a carbonyl group, such that the carbon atom (C-22) directly bonded to C-20 is an sp2 or sp3 hybridized carbon atom, i.e. bonded to 2 or 3 other atoms; and in which another of the CH2 groups may be replaced by phenylene, and where Q may optionally be substituted with one or more hydroxy or C1-C4-alkoxy groups.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: June 4, 2002
    Assignee: Leo Pharmaceutical Products Ltd. A/S (Løvens kemiske Fabrik Produktionsaktiesel skab)
    Inventors: Welf von Daehne, Gunnar Grue-Sørensen, Martin John Calverley, Claus Aage Svensgaard Bretting
  • Patent number: 6310226
    Abstract: The present invention relates to compounds of formula (I) in which formula X is hydrogen or hydroxy; R1 and R2 which may be the same or different, stand for hydrogen or C1-C5 hydrocarbyl; or R1 and R2, taken together with the carbon atom bearing the group X, can form a C3C8 carbocyclic ring; Q is methylene, ethylene, tri- or tetra-methylene and may optionally be substituted with an oxy group, —OR3, in which R3 is hydrogen, methyl or ethyl; Y is either a single bond or C1-C2 hydrocarbylene; and one or more carbons with in R1, R2, and/or Y may optionally be substituted with one or more fluorine atoms, or with a hydroxyl group. The compounds show anti-inflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: October 30, 2001
    Assignee: Leo Pharmaceutical Products Ltd.
    Inventors: Martin John Calverley, Henrik Pedersen
  • Patent number: 5994332
    Abstract: The present invention relates to compounds of formula (I) in which formula X is hydrogen or hydroxy; R.sup.1 and R.sup.2 stand for methyl or ethyl, or, when taken together with the carbon atom bearing the group X, can form a C.sub.3 -C.sub.5 carbocyclic ring; Q is either a single bond or a C.sub.1 -C.sub.8 hydrocarbylene in which one of any methylene groups not directly bonded to the carbonyl group may optionally be replaced by an oxygen atom (or methyl by hydroxy); Y is either a single bond or C.sub.1 -C.sub.8 hydrocarbylene; and derivatives of (I) in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo. The compounds show anti-inflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: November 30, 1999
    Assignee: Leo Pharmaceutical Products Ltd. A/S
    Inventor: Martin John Calverley
  • Patent number: 5710142
    Abstract: The invention relates to 20(S)-vitamin D compounds having the following formula ##STR1## where U and R' are as defined in the specification. The compounds have strong antiinflammatory and immunomodulating activity. There are also useful in the inhibition of proliferation of undesirable cells.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: January 20, 1998
    Assignee: Leo Pharmaceutical Products Ltd. A/S (Bovens Kemiske Fabrik Produktionsaktieselskab)
    Inventors: Martin John Calverley, Henrik Pedersen